Glenmark Pharmaceuticals Limited provided earnings guidance for the fiscal year 2023. For the year, the company expects revenue growth of 6% to 8%.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,035 INR | +1.52% | +2.12% | +20.93% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+20.93% | 3.53B | |
+21.41% | 44.12B | |
+23.44% | 22.71B | |
+18.22% | 15.15B | |
+13.03% | 13.61B | |
+61.49% | 13.34B | |
-8.55% | 6.84B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+15.65% | 5.63B |
- Stock Market
- Equities
- GLENMARK Stock
- News Glenmark Pharmaceuticals Limited
- Glenmark Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023